Xbrane Biopharma AB (CHIX:XBRANS) Cyclically Adjusted FCF per Share: kr-45,080.87 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:XBRANS Xbrane Biopharma AB CHIX:XBRANS
71 GF Score
Price kr3,825.00
GF Value kr2,435.92
! 6 Warning Signs
View Full Analysis

What is Xbrane Biopharma AB Cyclically Adjusted FCF per Share?

Xbrane Biopharma AB CHIX:XBRANS 71 Cyclically Adjusted FCF per Share is kr-45,080.87 as of Jun. 2026. GuruFocus rates CHIX:XBRANS with a GF Score™ of 71/100 and a GF Value™ of kr2,435.92. The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Xbrane Biopharma AB's adjusted free cash flow per share for the three months ended in Jun. 2026 was kr-0.843. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is kr-45,080.87 for the trailing ten years ended in Jun. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-08-31), Xbrane Biopharma AB's current stock price is kr3825.00. Xbrane Biopharma AB's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2026 was kr-45,080.87. Xbrane Biopharma AB's Cyclically Adjusted Price-to-FCF of today is .


Xbrane Biopharma AB  (CHIX:XBRANs) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Xbrane Biopharma AB Cyclically Adjusted FCF per Share Related Terms


Xbrane Biopharma AB Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Xbrane Biopharma AB's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xbrane Biopharma AB Cyclically Adjusted FCF per Share Chart

Xbrane Biopharma AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 -30,443.96 -50,700.00

Xbrane Biopharma AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -17,088.19 -16,730.19 -50,700.00 -77,235.00 -45,080.87

CHIX:XBRANS vs VRTX, REGN, MRNA: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Xbrane Biopharma AB's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xbrane Biopharma AB Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xbrane Biopharma AB's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Xbrane Biopharma AB's Cyclically Adjusted Price-to-FCF falls into.


CHIX:XBRANS
71GF Score
Xbrane Biopharma AB CHIX:XBRANS
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Xbrane Biopharma AB Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Xbrane Biopharma AB's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-0.843/134.6100*134.6100
=-0.843

Current CPI (Jun. 2026) = 134.6100.

Xbrane Biopharma AB Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201609 -28.238 101.138 -37.584
201612 -35.966 102.022 -47.455
201703 -26.421 102.022 -34.861
201706 -19.160 102.752 -25.100
201709 -19.495 103.279 -25.409
201712 -35.658 103.793 -46.245
201803 -20.828 103.962 -26.968
201806 -40.830 104.875 -52.407
201809 67.465 105.679 85.935
201812 79.837 105.912 101.470
201903 -117.450 105.886 -149.311
201906 -30.672 106.742 -38.680
201909 -82.357 107.214 -103.402
201912 5.578 107.766 6.967
202003 -76.580 106.563 -96.736
202006 13.036 107.498 16.324
202009 -78.752 107.635 -98.488
202012 -45.782 108.296 -56.906
202103 -0.511 108.360 -0.635
202106 -70.235 108.928 -86.795
202109 -56.852 110.338 -69.358
202112 -48.794 112.486 -58.391
202203 7.863 114.825 9.218
202206 -32.319 118.384 -36.749
202209 -48.666 122.296 -53.566
202212 -65.404 126.365 -69.671
202303 -37.365 127.042 -39.591
202306 -72.264 129.407 -75.170
202309 -60.881 130.224 -62.932
202312 -38.660 131.912 -39.451
202403 -9.293 132.205 -9.462
202406 -8.996 132.716 -9.124
202409 -3.171 132.304 -3.226
202412 0.050 132.987 0.051
202503 -7.559 132.825 -7.661
202506 -0.074 133.699 -0.075
202509 -5.862 133.480 -5.912
202512 -0.135 133.390 -0.136
202603 -0.943 133.560 -0.950
202606 -0.843 134.610 -0.843

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of kr-45,080.87 mean?
Xbrane Biopharma AB (CHIX:XBRANS) has a Cyclically Adjusted FCF per Share of kr-45,080.87 as of Jun. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Xbrane Biopharma AB and its competitors.
Is Xbrane Biopharma AB's Cyclically Adjusted FCF per Share too high?
Xbrane Biopharma AB's current Cyclically Adjusted FCF per Share is kr-45,080.87. Overall, Xbrane Biopharma AB has a GF Score™ of 71/100, reflecting its overall financial health beyond just this single metric.
How does Xbrane Biopharma AB's Cyclically Adjusted FCF per Share compare to VRTX and REGN?
Xbrane Biopharma AB's Cyclically Adjusted FCF per Share of kr-45,080.87 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Xbrane Biopharma AB and its competitors. Xbrane Biopharma AB's current Cyclically Adjusted FCF per Share is kr-45,080.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xbrane Biopharma AB stock overvalued right now?
Xbrane Biopharma AB (CHIX:XBRANS) has a current Cyclically Adjusted FCF per Share of kr-45,080.87. The stock's GF Value™ is kr2,435.92, compared to a current price of kr3,825.00 — trading 57% above its estimated fair value. The current Cyclically Adjusted FCF per Share is kr-45,080.87. Xbrane Biopharma AB's overall GF Score™ is 71/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Xbrane Biopharma AB (CHIX:XBRANS), the current Cyclically Adjusted FCF per Share is kr-45,080.87 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Xbrane Biopharma AB (CHIX:XBRANS) Overvalued in 2026?

Based on GuruFocus' analysis, Xbrane Biopharma AB stock appears to be overvalued. The current stock price of kr3,825.00 is trading 57% above its estimated GF Value™ of kr2,435.92.

Key valuation signals for CHIX:XBRANS:

  • Cyclically Adjusted FCF per Share: kr-45,080.87
  • GF Value™: kr2,435.92 vs. price of kr3,825.00 (57% above fair value)
  • GF Score™: 71/100 with 6 warning signs

No single metric tells the full story. See the CHIX:XBRANS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Xbrane Biopharma AB Business Description

Other Exchanges XBRANE:Sweden7XB0:Germany
Address Scheeles vag 5, Solna, SWE, 171 65
Xbrane Biopharma AB is a biotechnology company that develops biosimilars. The company follows drugs on already approved biological drugs that can be introduced at a lower price after the patent expires on the original drug. The company has a patented protein production platform with greater productivity than standard systems for producing proteins in E.coli host cells. The company's product candidate is Ximluci, a ranibizumab biosimilar (original drug Lucentis) used in the treatment of various eye diseases, mainly the wet form of age-related macular degeneration. Other products in preclinical stage of the company includes Xdivane and Xdarzane.
71GF Score

Get the complete analysis for CHIX:XBRANS

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr3,825.00
Price
kr2,435.92
GF Value